As the government moves ahead with its industrial plan, a new report signals it will have to start doing things differently.
A trial of methylprednisolone in kidney patients was halted recently because of safety concerns. But this doesn't affect people taking the drug for asthma, arthritis or other inflammatory conditions.
Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here's where they come from and how they work.
3D bioprinting of living cells and materials may contribute to faster and cheaper ways to create effective new drugs - and even reduce animal testing.
The state of Ohio filed a lawsuit against opioid manufacturers. Will their legal arguments hold up in court – and what will it mean for other cities and states going after big pharma?
Canada is the only nation with a broad public health system lacking universal coverage for pharmaceuticals. Despite fears that pharmacare would be too costly, it could end up saving Canadians money.
A push towards prescribing generic medications rather than their branded equivalents, as flagged in the budget, may have benefits beyond simple cost savings.
In many trials, patients have been told they're getting the sugar pill. They still got better.
Wider availability of the cystic fibrosis drug Kalydeco since May 1, 2017 means younger patients can now access it.
Herbal remedies can be dangerous, but so can drugs approved by the FDA.
The newer drugs for hepatitis C might mean fewer people are diagnosed with liver cancer.
A pirated movie won't kill you, but a counterfeit blood-thinner might. Australia needs stronger laws and tougher enforcement to counter fake drugs.
Alternative facts owe more to Aldous Huxley’s Brave New World than Orwell's 1984.
The Social Medwork is a website that promises patients legal access to medicines from overseas. How does it work? What are the risks? And why are patients turning to it to access the drugs they need?
Antipsychotic medications for delirium don't work and could harm, a new study shows. So what options are left?
Classing e-cigarettes as quit smoking aids could help rebrand the tobacco industry as a legitimate player in health policy. Here's why we should be concerned.
Why US$790m is not enough to win the war against antibiotic resistance.
With the right investment, an open source drug discovery system might compete with the traditional pharmaceutical industry to deliver the drugs we need.
Just like humans, corals live with myriad microscopic organisms. We are just starting to understand this unseen world.
Why drug maker Mylan's decision to introduce a half-price version of its EpiPen could be more than a publicity stunt.